J
Joshua Armenia
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 68
Citations - 15547
Joshua Armenia is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 30, co-authored 53 publications receiving 10006 citations. Previous affiliations of Joshua Armenia include National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression.
Goutam Chakraborty,Joshua Armenia,Ying Z. Mazzu,Subhiksha Nandakumar,Konrad H. Stopsack,Mohammad Omar Atiq,Kazumasa Komura,Kazumasa Komura,Lina E. Jehane,Rahim Hirani,Kalyani Chadalavada,Yuki Yoshikawa,Nabeela Khan,Yu Chen,Wassim Abida,Lorelei A. Mucci,Gwo-Shu Mary Lee,Gouri Nanjangud,Philip W. Kantoff +18 more
TL;DR: It is shown that patients with prostate cancer who have lost acopy of BRCA2 frequently lose a copy of tumor suppressor gene RB1; importantly, for the first time, it is demonstrated that co-loss of both genes in early prostate cancer is sufficient to induce a distinct biology that is likely associated with worse prognosis.
Journal ArticleDOI
CDK6 protects epithelial ovarian cancer from platinum-induced death via FOXO3 regulation
Alessandra Dall'Acqua,Maura Sonego,Ilenia Pellizzari,Ilenia Pellarin,Vincenzo Canzonieri,Sara D'Andrea,Sara Benevol,Roberto Sorio,Giorgio Giorda,Daniela Califano,Marina Bagnoli,Loredana Militello,Delia Mezzanzanica,Gennaro Chiappetta,Joshua Armenia,Barbara Belletti,Monica Schiappacassi,Gustavo Baldassarre +17 more
TL;DR: The data suggest that CDK6 represents an actionable target that can be exploited to improve platinum efficacy in EOC patients, and can be immediately transferred to the clinic to improve the outcome of E OC patients.
Journal ArticleDOI
ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D
Kazumasa Komura,Yuki Yoshikawa,Teppei Shimamura,Goutam Chakraborty,Travis Gerke,Kunihiko Hinohara,Kalyani Chadalavada,Seong Ho Jeong,Joshua Armenia,Shin-Yi Du,Ying Z. Mazzu,Kohei Taniguchi,Naokazu Ibuki,Clifford A. Meyer,Gouri Nanjangud,Teruo Inamoto,Gwo-Shu Mary Lee,Lorelei A. Mucci,Haruhito Azuma,Christopher Sweeney,Philip W. Kantoff +20 more
TL;DR: The result of ChIP‐sequencing analysis revealed that KDM5D preferably binds to promoter regions with coenrichment of the motifs of crucial transcription factors that regulate the cell cycle, which provides clues for a potential novel therapeutic approach for this subset of aggressive prostate cancer.
Journal ArticleDOI
Radiotherapy-induced miR-223 prevents relapse of breast cancer by targeting the EGF pathway.
Linda Fabris,S. Berton,Francesca Citron,Sara D'Andrea,Ilenia Segatto,Milena S. Nicoloso,Samuele Massarut,Joshua Armenia,Gaetano Zafarana,Simona Rossi,Simona Rossi,Cristina Ivan,Tiziana Perin,Jayant S. Vaidya,Michele Avanzo,Mario Roncadin,Monica Schiappacassi,Robert G. Bristow,George A. Calin,Gustavo Baldassarre,Barbara Belletti +20 more
TL;DR: The results demonstrate that IORT elicits effects that go beyond the direct killing of residual tumor cells, and prompts to the use of anti-EGFR treatments, in a peri-operative treatment schedule, aimed to timely treat BC patients and restrain recurrence formation.
Journal ArticleDOI
p27kip1 controls H-Ras/MAPK activation and cell cycle entry via modulation of MT stability
Linda Fabris,Stefania Berton,Ilenia Pellizzari,Ilenia Segatto,Sara D'Andrea,Joshua Armenia,Riccardo Bomben,Monica Schiappacassi,Valter Gattei,Mark R. Philips,Andrea Vecchione,Barbara Belletti,Gustavo Baldassarre +12 more
TL;DR: It is demonstrated that p27kip1 controls cell cycle entry also through a CDK-independent function, by regulating microtubule stability, and is identified as a regulatory axis controlling the G1/S-phase transition of the cell cycle and finely controlling the spatiotemporal activation of the Ras-MAPK signaling pathway.